Paul Romesser
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paul Romesser as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07927998 · A Study of Retifanlimab After Chemoradiation in People With Anal CancerMemorial Sloan Kettering Cancer Center · recruiting · Anal Squamous Cell Carcinoma, Anal Cancer, Anal Carcinoma · principal investigator
- N/ANCT06637462 · A Study of Response to Standard Treatment Before Surgery in People With Rectal CancerMemorial Sloan Kettering Cancer Center · recruiting · Rectal Cancer, Adenocarcinoma of the Rectum · principal investigator
- Ph2NCT05657873 · A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)Memorial Sloan Kettering Cancer Center · recruiting · Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Leveraging Radiation-Induced Senescence and PTPN2 Inhibition to Enhance Immune-Mediated Tumor Control in Rectal CancerR37CA304010 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2025 to 2026 · $730,398 awarded in 2026Same name and institution; not confirmed by an ID
- Investigating the contribution of cellular senescence to the efficacy of radiation therapy.K08CA255574 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2021 to 2025 · $217,814 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:38 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.N Engl J Med · 20221,341 citationsRCR 92.5
- Nonoperative Management of Mismatch Repair-Deficient Tumors.N Engl J Med · 2025193 citationsRCR 40.4
- Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.Clin Cancer Res · 202177 citationsRCR 3.4
- 43 citationsRCR 5.0
- A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.Clin Cancer Res · 202431 citationsRCR 3.7
- 8 citationsRCR 0.9